tiprankstipranks
Microbix Biosystms (TSE:MBX)
:MBX
Canadian Market

Microbix Biosystms (MBX) Earnings Dates, Call Summary & Reports

Compare
32 Followers

Earnings Data

Report Date
May 14, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
Last Year’s EPS
<0.01
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Feb 13, 2025
|
% Change Since: 0.00%
|
Next Earnings Date:May 14, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant positive achievements, including strong growth in core business revenues, expanded gross margins, and strategic advancements such as achieving IVDR accreditation and initiating a recombinant antigen program. However, there were some challenges, notably the revenue decline due to the absence of a previous year's milestone payment and delays in QAPs revenue. The positive aspects, particularly the strong growth and strategic expansions, outweigh the challenges.
Company Guidance
During the call, Microbix Biosystems provided a comprehensive overview of their financial and operational performance for fiscal Q1 2025. The company reported revenues of over $6 million, a significant increase from $4.3 million the prior year when excluding $4.1 million of nonrecurring milestone payments. Gross margins expanded to 62% from 49% in the previous year, showcasing improvements in efficiency and cost control. Operational expenditures were down year-over-year, contributing to strong net earnings of $856,000. The company also highlighted a 40% growth in recurring core businesses and the successful buyback of approximately 2.5 million shares over the first four months. Additionally, they noted strong cash flow with nearly $3 million from the exercise of warrants and options. Microbix emphasized strategic expansions in their product offerings, including moving into recombinant antigens and new quality assessment products (QAPs) in oncology and genetic testing markets, indicating a broadened total addressable market and future growth potential.
Strong Revenue Growth in Core Business
Achieved 40% growth in recurring core businesses with revenues over $6 million, compared to $4.3 million the prior year. This was primarily from recurring sales.
Expanded Gross Margins
Gross margins expanded to 62% compared to 49% in the previous year, reflecting improvements in manufacturing processes and operational efficiencies.
Successful Share Buyback and Strong Cash Position
Bought back approximately $2.5 million shares, with additional cash inflow from warrant exercises, bringing nearly $3 million of additional cash. Maintained a strong cash position.
IVDR Accreditation Achievement
Successfully achieved IVDR accreditation for sales in the European Union, indicating progress in meeting higher regulatory standards.
Recombinant Antigen Program Initiation
Initiated a recombinant antigen program, expanding total addressable markets and enhancing product offerings.
---

Microbix Biosystms (TSE:MBX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

TSE:MBX Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 14, 20252025 (Q2)
- / -
0.003
Feb 13, 20252025 (Q1)
- / <0.01
0.018-66.67% (-0.01)
Dec 19, 20242024 (Q4)
- / <0.01
0.014-78.57% (-0.01)
Aug 14, 20242024 (Q3)
- / <0.01
-0.006133.33% (<+0.01)
May 15, 20242024 (Q2)
- / <0.01
0
Feb 14, 20242024 (Q1)
- / 0.02
-0.009300.00% (+0.03)
Dec 21, 20232023 (Q4)
>-0.01 / 0.01
-0.009255.56% (+0.02)
Aug 10, 20232023 (Q3)
0.00 / >-0.01
0.004-250.00% (-0.01)
May 11, 20232023 (Q2)
>-0.01 / 0.00
0.005
Feb 09, 20232023 (Q1)
>-0.01 / >-0.01
0.006-250.00% (-0.01)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

TSE:MBX Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 13, 2025C$0.48C$0.480.00%
Dec 19, 2024C$0.36C$0.37+2.78%
Aug 14, 2024C$0.34C$0.340.00%
May 15, 2024C$0.32C$0.35+9.37%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Microbix Biosystms (TSE:MBX) report earnings?
Microbix Biosystms (TSE:MBX) is schdueled to report earning on May 14, 2025, TBA Not Confirmed.
    What is Microbix Biosystms (TSE:MBX) earnings time?
    Microbix Biosystms (TSE:MBX) earnings time is at May 14, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is TSE:MBX EPS forecast?
          Currently, no data Available
          ---
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis